infection: intraviral (i.e., virus-virus) and virus-host interactions. Intraviral protein-protein interactions are essential to virus replication and occur normally among viral structural proteins, which play an important role in different stages of virus life cycle such as assembly and release. Virus-host interactions involving both structural and non-structural viral proteins are believed to serve more complex roles in virus replication and pathogenesis. By hijacking cellular machineries through protein interactions, viruses can evade host immunity and replicate in the hosts, causing diseases. Virus-host interactions are also commandeered to support viral replication and transmission processes such as virus entry, virus genome transcription, and virus release. Protein interactions are at the heart of virus infections and the associated diseases. Thus, a study of protein interactions and the molecular principles that underlie them is critical towards the understanding of virus replication and pathogenesis. Viral protein-protein interactions can be also targeted for the development of antiviral therapies in the future.
Several approaches with high-throughput potential have been developed to study proteinprotein interactions. Of these, the yeast-two-hybrid (Y2H) system is viewed as the standard assay for the study of protein-protein interactions ). This system has been used previously to study viral protein-protein interactions in cells (Calderwood et al., 2007; de Chassey et al., 2008; Fossum et al., 2009; Rozen et al., 2008; Uetz et al., 2006) . The Y2H system utilizes a reporter gene which expresses only two fusion proteins that interact appears to require the fusion proteins to be imported to the nucleus, which may limit the sensitivity for probing interactions which occur in the cytoplasm. Additional concern is that the discrepancy has been demonstrated for identified interactions in comparative studies using Y2H systems ). Limitations of Y2H highlight a need for development of other protein-protein interaction assays that can be used independently to study protein interactions or as an alternative approach to validate the biological significance of an interaction identified by Y2H.
One such approach is the Split Luciferase Complementation Assay (SLCA), where a luciferase protein is reconstituted when two fusion proteins interact (Cissell et al., 2009; Fujikawa Kato, 2007; Kaihara et al., 2003; Paulmurugan Gambhir, 2003; Paulmurugan, Umezawa, Gambhir, 2002) . The assay is based on the principle that N-and C-terminal domains of luciferase alone do not emit luminescence; however, if fused to interacting proteins the two non-functional halves can be brought into close enough proximity to form a functional enzyme as a result of appropriate specific protein interactions (Fig. 1A) . Thus, through SLCA, the specific protein-protein interactions can be detected quantitatively by measuring reassembled luciferase activity in a microplate luminometer. Due to its sensitive and highly dynamic nature for detecting protein-protein interactions, this assay is becoming an increasingly popular tool used to study protein-protein interactions in cell biology and plant science (Cissell et al., 2009; Fujikawa Kato, 2007; Kaihara et al., 2003; Paulmurugan Gambhir, 2003; Paulmurugan et al., 2002 ). An additional advantage is that unlike split-GFP assay (also known as bimolecular fluorescent complementation assay, BiFC), the protein complexes formed through SLCA are largely reversible so the interactions detected are dynamic in nature . This assay has been used previously to study the homodimerization of herpes simplex virus 1 thymidine kinase ). In the current work, we sought to apply the Split Luciferase Complementation Assay to the detection of intraviral protein-protein interactions using a well-studied influenza B PA-PB1 interaction as a model system. Previous studies have shown that the N-terminal 25 amino acid residues of influenza B PB1 (PB1 1-25 B) are sufficient for binding of influenza B PA protein (Deng et al., 2011; Wunderlich et al., 2010; Wunderlich et al., 2009 ).
Renilla luciferase (RL) was selected as an enzyme for the assay and a split approach of Renilla luciferase was employed involving an N-terminal fragment consisting of amino acids 1-229 (termed LN) and a C-terminal fragment consisting of amino acids 230-311 (termed LC) (Fig. 1A) . This design has been validated previously in an SLCA for the detection of protein-protein interactions (Fujikawa Kato, 2007) . Considering that the orientation of fusion proteins may sterically affect the association of the RL fragments subsequently inhibiting enzymatic activity, fusion constructs representing the influenza B PA and PB1 proteins were generated in multiple configurations (Fig. 1B) . To express influenza B viral polymerase proteins, the eukaryotic expression vector pPRE was used under the control of both the cytomegalovirus (CMV) immediate-early promoter and the bovine growth hormone polyadenylation signal as described previously (Patnaik et al., 2002; Wang et al., 2010) . Three steps were required to generate various expression vectors used in the SLCA study. First, N-terminal fragment (residues 1-229 of Renilla luciferase) were amplified from the Renilla luciferase expression vector pGL4.76 (Promega) and inserted into the pPRE vector by digestion with EcoRI/NotI and then re-ligated. The resultant vector was designated pLN. Second, the same method was used to generate the vector pLC for expression of the C-terminal fragment (residues 230-311 of Renilla luciferase). Third, complete open-reading frames encoding PA and PB1 were amplified from an influenza B/ Lee/40 reverse genetic system (Deng et al., 2011) and fused via a protein linker (GGGS x 2) to the N-terminus or C-terminus of the LN or LC fragments, respectively, which resulted in two groups of fusion plasmids: the PA group (PA-LN, PA-PC, LN-PA, and LC-PA) and the PB1 group (PB1-LC, LN-PB1, and LC-PB1). Primers and sequence information for each construct is available upon request. Initial screening of all possible combinations of SLCA PA/PB1 pairs for reconstituted RL enzymatic activity resulted in the identification of an interacting PA/PB1 pair (PA-LC and LN-PB1), which exhibited the highest activity (~15000RLU) (Fig. 1C) . Thus, the PA-LC and LN-PB1 pair became the focus of our study.
COS-1 cells were cultured in Dulbecco's minimal essential medium (DMEM) supplemented with 10% fetal bovine serum and grown on 12-well plates. Cells were then transfected using TransIT-LT1 (Mirus) following the procedures outlined by the manufacturer with PA-LC and LN-PB1 or LN empty vector (0.5 μg each plasmid). At 48 h post-transfection, cell lysates were collected to measure luciferase activity as a function of protein-protein interactions using a luciferase assay system (Promega) following the manufacturer's recommendations. Transfection with both PA-LC and empty LN vectors served as a specificity control. As demonstrated in Fig. 1D , transfections involving PA-LC/LN constructs resulted in very low background signals (~120RLU), while transfections with a PA/PB1 pair (PA-LC/LN-PB1) produced ~4800RLU. ~40-fold increase of luciferase activity against the background observed in the PA-LC/LN-PB1 pair indicated that SLCA is robust and specific in detecting PA-PB1 interaction.
This approach was then validated by targeting the PA-PB1 interaction interface. To designa rational mutation that disrupts the PA-PB1 interface, we took advantage of a recently solved high-resolution structure of the influenza A RNA polymerase (PA-PB1) complex, and used it as a template to model the influenza B PA-PB1 interface (He et al., 2008; Obayashi et al., 2008) . Due to the lack of any deletions or insertions and high sequence identity (~33 and 60% for PA and PB1, respectively) between influenza A and B virus polymerase proteins (data not shown), the influenza B PA-PB1 interaction interface can be readily modeled on the influenza A virus template ( Fig. 2A) . Examining the modeled PA-PB1 interface revealed that some of the key residues within the N-terminal domain of PB1 (i.e., PA-binding domain) that contribute to the PA-PB1 interface are identical between the two viruses ( Fig.  2A) . For example, three nonpolar helical residues (P5, L8, and F9) in the influenza A PB1 N-terminal domain that have been shown to be critical in the helical stability and provide apolar contacts with PA are present at the same positions in the influenza B PB1 protein (He et al., 2008; Obayashi et al., 2008) . P5 and Y6 were chosen as targeted residues for sitespecific mutagenesis because the structural and biological importance of these two residues in the influenza A PA-PB1 interaction has been well-elucidated (He et al., 2008; Obayashi et al., 2008) . As demonstrated in Fig. 2B , mutation of the P5 or Y6 residue to an alanine residue had no obvious effect on fusion protein expression but inhibited PB1 binding to PA by approximately 65% (Y6A) and 73% (P5A), respectively, further indicating the assays' specificity in detecting PA-PB1 interaction of influenza B virus.
In summary, a simple and specific split luciferase complementation assay was developed which can be used for detecting viral protein-protein interactions. SLCA is straightforward and can be performed easily using a luminometer and standard molecular biology and cell culture reagents. With the potential automation in a high-throughput screening format, this assay can be used alone or in conjunction with Y2H or other assays to study viral proteinprotein interactions and to reveal the intricate networks that viruses employ to benefit their replication in the host. This information is useful for the design novel antiviral agents to treat viral diseases and overcome drug resistance associated with current antiviral drugs. 
